Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Roche Products Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Designation or determination (21)
Australian public assessment report (AusPar) (11)
Prescription medicine decision summary (5)
Prescription medicine registration (2)

Date

2023 (3)
2022 (2)
2021 (7)
2020 (9)
2019 (6)
2018 (6)
2017 (4)
2016 (1)
2014 (1)

Search

Sponsor content

39 result(s) found, displaying 11 to 20

Notice for tocilizumab (Roche Products Pty Limited)

27 September 2021

Designation or determination

Provisional approval
Notice for casirivimab and imdevimab (Roche Products Pty Limited)

20 August 2021

Designation or determination

Provisional approval
AusPAR: Tocilizumab (rch)

3 September 2020

Australian public assessment report (AusPar)

New AusPAR for Actemra (tocilizumab) for the treatment of systemic juvenile idiopathic arthritis
Notice for risdiplam (Roche Products Pty Limited)

30 June 2020

Designation or determination

Orphan drug
Notice for risdiplam (Roche Products Pty Limited)

30 June 2020

Designation or determination

Priority review
AusPAR: Atezolizumab

18 June 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Atezolizumab
AusPAR: Baloxavir marboxil

11 June 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Baloxavir marboxil
Rozlytrek

25 May 2020

Prescription medicine decision summary

Australian prescription medicine decision summary
Xofluza

2 March 2020

Prescription medicine decision summary

Australian prescription medicine decision summary
Notice for atezolizumab (Roche Products Pty Limited)

10 January 2020

Designation or determination

Priority review

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.